Table 2.
Results of the network meta-analysis in novel oral anticoagulants vs. warfarina
| Stroke or systemic embolism | Any stroke | Hemorrhagic stroke | Ischemic stroke | Disabling or fatal stroke | All-cause mortality | MI | Major bleeding | GI bleeding | ICH | Any bleeding | |
| Warfarin vs. dabigatran 110 mg | 1.10 (0.90;1.35) | 1.09 (0.88;1.35) | 3.46 (1.80;6.14) | 0.89 (0.70;1.11) | 1.06 (0.82;1.37) | 1.10 (0.96;1.25) | 0.73 (0.52;1.03) | 1.25 (1.07;1.46) | 0.91 (0.69;1.19) | 3.38 (2.19;5.41) | 1.36 (1.26;1.46) |
| Warfarin vs. dabigatran 150 mg | 1.53 (1.23;1.92) | 1.55 (1.22;1.95) | 4.09 (2.06;7.51) | 1.32 (1.03;1.67) | 1.51 (1.12;1.98) | 1.14 (0.99;1.30) | 0.72 (0.50;0.99) | 1.07 (0.92;1.24) | 0.66 (0.52;0.82) | 2.52 (1.65;3.74) | 1.15 (1.06;1.24) |
| Warfarin vs. apixaban | 1.27 (1.05;1.52) | 1.27 (1.05;1.52) | 2.02 (1.35;2.94) | 1.09 (0.88;1.32) | 1.46 (1.08;1.91) | 1.13 (1.01;1.26) | 1.15 (0.85;1.51) | 1.44 (1.26;1.67) | 1.15 (0.87;1.48) | 2.44 (1.72;3.38) | 1.46 (1.37;1.56) |
| Warfarin vs. rivaroxaban | 1.14 (0.97;1.37) | 1.12 (0.94;1.34) | 1.76 (1.15;2.71) | 1.02 (0.83;1.21) | 1.28 (0.99;1.62) | 1.10 (0.97;1.23) | 1.10 (0.84;1.38) | 0.98 (0.84;1.13) | 0.69 (0.55;0.83) | 1.57 (1.09;2.23) | 0.98 (0.90;1.06) |
| Warfarin vs. edoxaban 30 mg | 0.92 (0.77;1.10) | 0.87 (0.76;1.02) | 3.12 (1.99;4.66) | 0.69 (0.59;0.81) | 0.89 (0.71;1.13) | 1.16 (1.04;1.29) | 0.83 (0.67;1.02) | 2.16 (1.85;2.52) | 1.50 (1.19;1.89) | 3.33 (2.34;4.65) | 1.58 (1.45;1.71) |
| Warfarin vs. edoxaban 60 mg | 1.30 (1.07;1.58) | 1.14 (0.96;1.34) | 1.88 (1.30;2.63) | 0.99 (0.83;1.22) | 1.03 (0.80;1.30) | 1.10 (0.99;1.22) | 1.07 (0.85;1.35) | 1.27 (1.10;1.45) | 0.82 (0.67;0.99) | 2.22 (1.63;2.97) | 1.19 (1.11;1.28) |
GI, gastrointestinal; ICH, intracranial hemorrhage; MI, myocardial infarction; NR, not reported.
aResults are presented as odds ratios (95% confidence intervals). Results shown in boldface are significantly different.